Company intelligence / Profile preview

Anza Therapeutics

Concord, California, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Anza Therapeutics developed immunotherapies and therapeutic vaccines for cancer and infectious diseases, advancing a hepatitis C vaccine (in partnership with Cerus) and the candidate ANZ-100 for liver cancer. Programs were discontinued and the company is now out of business.[1][2][5]

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineImmunostimulantTherapeutic vaccine
Industry: Biotech

Partnerships

Cerus Corporation

Beyond the preview

Go deeper on Anza Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anza Therapeutics.

Explore the full profile